Arthritis Program, University Health Network, Toronto, ON, Canada; Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Arthritis Program, University Health Network, Toronto, ON, Canada; Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Semin Cell Dev Biol. 2020 May;101:87-103. doi: 10.1016/j.semcdb.2019.10.014. Epub 2019 Nov 19.
Most chronic diseases involving inflammation have a fibrotic component that involves remodeling and excess accumulation of extracellular matrix components. Left unchecked, fibrosis leads to organ failure and death. Mesenchymal stromal cells (MSCs) are emerging as a potent cell-based therapy for a wide spectrum of fibrotic conditions due to their immunomodulatory, anti-inflammatory and anti-fibrotic properties. This review provides an overview of known mechanisms by which MSCs mediate their anti-fibrotic actions and in relation to animal models of pulmonary, liver, renal and cardiac fibrosis. Recent MSC clinical trials results in liver, lung, skin, kidney and hearts are discussed and next steps for future MSC-based therapies including pre-activated or genetically-modified cells, or extracellular vesicles are also considered.
大多数涉及炎症的慢性疾病都有一个纤维化成分，涉及细胞外基质成分的重塑和过度积累。如果不加控制，纤维化会导致器官衰竭和死亡。间充质基质细胞（MSCs）由于其免疫调节、抗炎和抗纤维化特性，正成为一种广泛用于治疗各种纤维化疾病的有效细胞疗法。这篇综述概述了 MSCs 介导其抗纤维化作用的已知机制，并与肺部、肝脏、肾脏和心脏纤维化的动物模型有关。还讨论了最近 MSCs 在肝脏、肺部、皮肤、肾脏和心脏的临床试验结果，并考虑了未来基于 MSCs 的治疗方法的下一步措施，包括预激活或基因修饰细胞或细胞外囊泡。
